JP5974180B2 - ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 - Google Patents

ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 Download PDF

Info

Publication number
JP5974180B2
JP5974180B2 JP2015529664A JP2015529664A JP5974180B2 JP 5974180 B2 JP5974180 B2 JP 5974180B2 JP 2015529664 A JP2015529664 A JP 2015529664A JP 2015529664 A JP2015529664 A JP 2015529664A JP 5974180 B2 JP5974180 B2 JP 5974180B2
Authority
JP
Japan
Prior art keywords
pyrazol
pyridin
propyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015529664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531774A (ja
JP2015531774A5 (OSRAM
Inventor
ソー バエ、ユン
ソー バエ、ユン
ジュ ハ、フン
ジュ ハ、フン
イン リー、ケー
イン リー、ケー
ヘ ソン、キュン
ヘ ソン、キュン
Original Assignee
エウハ ユニヴァーシティ−インダストリー コラボレーション ファウンデーション
エウハ ユニヴァーシティ−インダストリー コラボレーション ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エウハ ユニヴァーシティ−インダストリー コラボレーション ファウンデーション, エウハ ユニヴァーシティ−インダストリー コラボレーション ファウンデーション filed Critical エウハ ユニヴァーシティ−インダストリー コラボレーション ファウンデーション
Publication of JP2015531774A publication Critical patent/JP2015531774A/ja
Publication of JP2015531774A5 publication Critical patent/JP2015531774A5/ja
Application granted granted Critical
Publication of JP5974180B2 publication Critical patent/JP5974180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015529664A 2012-08-27 2013-08-02 ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物 Active JP5974180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2012-0093936 2012-08-27
KR1020120093936A KR101633957B1 (ko) 2012-08-27 2012-08-27 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
PCT/KR2013/006985 WO2014035070A1 (ko) 2012-08-27 2013-08-02 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물

Publications (3)

Publication Number Publication Date
JP2015531774A JP2015531774A (ja) 2015-11-05
JP2015531774A5 JP2015531774A5 (OSRAM) 2015-12-17
JP5974180B2 true JP5974180B2 (ja) 2016-08-23

Family

ID=50183832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529664A Active JP5974180B2 (ja) 2012-08-27 2013-08-02 ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物

Country Status (9)

Country Link
US (1) US10047067B2 (OSRAM)
EP (1) EP2889032B1 (OSRAM)
JP (1) JP5974180B2 (OSRAM)
KR (1) KR101633957B1 (OSRAM)
CN (1) CN104755077B (OSRAM)
ES (1) ES2734264T3 (OSRAM)
PL (1) PL2889032T3 (OSRAM)
TR (1) TR201909923T4 (OSRAM)
WO (1) WO2014035070A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101826208B1 (ko) 2016-02-05 2018-02-06 경북대학교 산학협력단 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
TW202133845A (zh) 2019-11-21 2021-09-16 韓商三進製藥股份有限公司 用於預防或治療眼部疾病之眼用組合物
KR102277665B1 (ko) * 2020-02-05 2021-07-15 바이오그래핀 주식회사 그래핀 기반 신장 질환 치료용 조성물
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
JP7553595B2 (ja) * 2020-04-08 2024-09-18 アプタバイオ セラピューティクス インコーポレイテッド 造影剤誘発急性腎不全治療剤
JP7539485B2 (ja) * 2020-04-13 2024-08-23 アプタバイオ セラピューティクス インコーポレイテッド ピラゾール誘導体の肺線維症治療剤
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
WO2022120194A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물
IL307454A (en) 2021-04-07 2023-12-01 Battelle Memorial Institute Technologies for rapid design, construction, testing, learning to identify and use non-viral vectors
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN119504599B (zh) * 2024-11-18 2025-09-26 安徽医科大学 一种用于治疗肾脏纤维化的吡唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
AU2697092A (en) 1991-10-08 1993-05-03 Nippon Soda Co., Ltd. Pyrazole derivative and agrohorticultural bactericide containing same
JP2003098120A (ja) 2001-09-26 2003-04-03 Tokyo Weld Co Ltd 外観検査装置
JP4189850B2 (ja) 2002-05-20 2008-12-03 味の素株式会社 線維化病変組織修復剤
KR20040094464A (ko) * 2003-05-02 2004-11-10 학교법인 이화학당 피리디닐 피라졸 유도체
WO2006129587A1 (ja) 2005-05-30 2006-12-07 Genecare Research Institute Co., Ltd. ピラゾロン誘導体を含有する医薬組成物
CN101511818B (zh) * 2006-09-01 2013-05-08 大塚农业科技株式会社 N-吡啶基哌啶化合物、其制备方法及有害生物防治剂
KR100942382B1 (ko) * 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
KR101280198B1 (ko) 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물

Also Published As

Publication number Publication date
KR20140027833A (ko) 2014-03-07
JP2015531774A (ja) 2015-11-05
EP2889032A1 (en) 2015-07-01
EP2889032B1 (en) 2019-05-08
KR101633957B1 (ko) 2016-06-27
US20150218125A1 (en) 2015-08-06
CN104755077B (zh) 2018-05-15
US10047067B2 (en) 2018-08-14
PL2889032T3 (pl) 2019-09-30
TR201909923T4 (tr) 2019-07-22
ES2734264T3 (es) 2019-12-05
CN104755077A (zh) 2015-07-01
WO2014035070A1 (ko) 2014-03-06
EP2889032A4 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
JP5974180B2 (ja) ピラゾール誘導体を含む腎臓疾患の予防または治療用組成物
JP6812564B2 (ja) 肝疾患治療剤
KR101630432B1 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
JP6635527B2 (ja) 高尿酸血症又は痛風の治療又は予防用化合物
US20120232117A1 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
KR101302315B1 (ko) 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
KR20180086497A (ko) sGC 자극제를 포함하는 고체 분산물
EP2682392A2 (en) Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same
WO2002006249A1 (en) Method for producing 1-substituted-1,2,3-triazole derivative
EP4105206A1 (en) Novel pyrazole derivative
CN113527153A (zh) 一类抑制肠道炎症反应的活性化合物
KR101683362B1 (ko) 소양증 개선 활성을 갖는 벤즈옥사졸 유도체
CN112079744B (zh) 芳香酰腙衍生物及其作为na抑制剂的应用
RU2846904C1 (ru) Новое производное пиразола
US20250387375A1 (en) Sofalcone derivatives and medical use thereof
CN106032378B (zh) 新型arb化合物及其用途
CN106536519A (zh) 唑苯衍生物的晶体
CN118084898A (zh) iCRT14衍生物及其制备方法和应用
CN104072501B (zh) 一种治疗阴道炎的化合物及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150424

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160715

R150 Certificate of patent or registration of utility model

Ref document number: 5974180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250